Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
State approval moves Regional One’s new hospital forward — thousands of jobs and big economic impact projected.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results